BIOCON

Biocon Share Price

₹336.35 +4.85 (1.46%)

26 Nov, 2024 01:24

SIP TrendupStart SIP in BIOCON

Start SIP

Performance

  • Low
  • ₹334
  • High
  • ₹339
  • 52 Week Low
  • ₹231
  • 52 Week High
  • ₹396
  • Open Price₹335
  • Previous Close₹332
  • Volume1,449,701

Investment Returns

  • Over 1 Month + 4.25%
  • Over 3 Month -4.34%
  • Over 6 Month + 5.29%
  • Over 1 Year + 42.91%
SIP Lightning

Smart Investing Starts Here Start SIP with Biocon for Steady Growth!

Invest Now

Biocon Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 28.1
  • PEG Ratio
  • 0.1
  • Market Cap Cr
  • 40,382
  • P/B Ratio
  • 1.6
  • Average True Range
  • 11.31
  • EPS
  • 11.61
  • Dividend Yield
  • 0.1
  • MACD Signal
  • -3.85
  • RSI
  • 52.12
  • MFI
  • 65.77

Biocon Financials

Biocon Technicals

EMA & SMA

Current Price
₹336.35
+ 4.85 (1.46%)
pointer
  • stock-down_img
  • Bullish Moving Average 11
  • stock-up_img
  • Bearish Moving Average 5
  • 20 Day
  • ₹330.93
  • 50 Day
  • ₹337.99
  • 100 Day
  • ₹338.04
  • 200 Day
  • ₹323.69

Resistance and Support

336.28 Pivot Speed
  • R3 344.42
  • R2 341.68
  • R1 339.02
  • S1 333.62
  • S2 330.88
  • S3 328.22

What's your outlook on Biocon?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Biocon Limited is India’s leading biopharmaceutical company, offering innovative and affordable therapies for diabetes, cancer, and autoimmune diseases. With over 13,500 employees, Biocon serves 120+ countries, focusing on generics, biosimilars, research services, and novel biologics.

Biocon (Nse) has an operating revenue of Rs. 14,894.10 Cr. on a trailing 12-month basis. An annual revenue growth of 35% is outstanding, Pre-tax margin of 11% is healthy, ROE of 5% is fair but needs improvement. The company has a debt to equity of 65%, which is bit higher. The stock from a technical standpoint is trading below to its 50DMA and close to its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. It is currently FORMING a base in its weekly chart and is trading around 16% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 44 which is a POOR score indicating inconsistency in earnings, a RS Rating of 59 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C- which is evident from recent supply seen, Group Rank of 67 indicates it belongs to a poor industry group of Medical-Biomed/Biotech and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Biocon Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-10-30 Quarterly Results
2024-08-08 Quarterly Results
2024-05-16 Audited Results & Final Dividend
2024-02-08 Quarterly Results
2023-11-10 Quarterly Results
Date Purpose Remarks
2024-07-05 FINAL Rs.0.50 per share(10%)Final Dividend
2023-07-07 FINAL Rs.1.50 per share(30%)Final Dividend
2022-07-01 FINAL Rs.0.50 per share(10%)Final Dividend

Biocon F&O

Biocon Shareholding Pattern

60.64%
7.97%
6.23%
5.93%
0.02%
14.57%
4.64%

About Biocon

Biocon limited is a biopharmaceutical company in India and it is Asia's largest biotechnology company. The company was founded by Kiran Mazumdar-Shaw in 1978 and is headquartered in Bengaluru, India. The company has more than 16,545 employees as on March 2023. It focuses on all phases of the product cycle from researching to development and then introducing them to the market. They mainly concentrate on the research and development of advanced therapies for the treatment of cancer, diabetes, and autoimmune disease. The company's medicines are helping the lives of patients in more than 120 countries by providing access to all their medicines and therapies. 

Some of Biocon's important brands in India are INSUGEN (rh-insulin), BIOMAb EGFR (Nimotuzumab), CANMAb (Trastuzumab),KRABEVA (Bevacizumab), ALZUMAb(Itolizumab), BLISTO (Glimepiride + Metformin), BASALOG (Glargine) & so on. 

View More
  • NSE Symbol
  • BIOCON
  • BSE Symbol
  • 532523
  • Managing Director & CEO
  • Mr. Siddharth Mittal
  • ISIN
  • INE376G01013

Similar Stocks to Biocon

Biocon FAQs

Biocon share price is ₹336 As on 26 November, 2024 | 01:10

The Market Cap of Biocon is ₹40382.2 Cr As on 26 November, 2024 | 01:10

The P/E ratio of Biocon is 28.1 As on 26 November, 2024 | 01:10

The PB ratio of Biocon is 1.6 As on 26 November, 2024 | 01:10

Biocon has an operating revenue of Rs.7,290.70 Cr. on a trailing 12-month basis. An annual revenue growth of 14% is good, Pre-tax margin of 16% is great. However, analysts are of mixed views on the stock.

Biocon Ltd. has declared 17 dividends since July 1, 2004.

The stock price CAGR of Biocon Limited for 10 Years is 24%, 5 Years is 17%, 3 Years is 5%, 1 Year is -21%.

The debt-to-equity ratio of Biocon Limited is 39% which signals a healthy balance sheet.

The ROE of Biocon Limited is 9% which is fair but needs improvement.

Mr. Siddharth Mittal is the Managing Director and CEO of Biocon Limited.

According to the record analysis of moneyworks4me, Biocom limited is an average quality company. 

The company's shares can be bought online by opening a demat account with 5paisa in either web or app.

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23